Tolvaptan works by blocking a hormone receptor in your kidneys that controls how much water your body retains. Specifically, it blocks vasopressin V2 receptors, which prevents the hormone vasopressin (also called ADH, or antidiuretic hormone) from signaling your kidneys to reabsorb water. The result is that your kidneys excrete large amounts of water without flushing out sodium or other electrolytes, a process called aquaresis.
This mechanism makes tolvaptan useful for two very different conditions: dangerously low sodium levels (hyponatremia) and a genetic kidney disease called autosomal dominant polycystic kidney disease (ADPKD). Understanding the drug’s mechanism helps explain both uses, the side effects you can expect, and why it requires close monitoring.
Aquaresis vs. Regular Diuresis
Most diuretics, like furosemide, work by forcing your kidneys to excrete both water and electrolytes, especially sodium. Tolvaptan does something fundamentally different. It causes electrolyte-free water excretion, meaning it removes excess water from your body while leaving sodium and potassium levels relatively untouched.
This distinction matters in practice. Research comparing the two approaches in hospitalized heart failure patients found that combining tolvaptan with furosemide removed excess water evenly from both inside and outside cells, while furosemide alone primarily pulled water from outside cells, including from blood vessels. That difference can affect blood pressure, kidney perfusion, and how quickly a patient stabilizes.
Because tolvaptan selectively removes water, the concentration of sodium in your blood rises. Your blood doesn’t gain sodium; it just has less water diluting the sodium already there. This is why the drug is effective for hyponatremia, where the core problem is too much water relative to sodium rather than too little sodium overall.
How It Treats Low Sodium Levels
Hyponatremia, defined as a serum sodium level below 135 mEq/L, is the most common electrolyte disorder in hospitalized patients. It can cause confusion, nausea, seizures, and in severe cases, coma. Tolvaptan addresses it by shedding the excess water that’s diluting blood sodium.
The landmark clinical trials (SALT-1 and SALT-2) tested tolvaptan against placebo in patients with both euvolemic and hypervolemic hyponatremia. By day 4, patients on tolvaptan saw their sodium rise by an average of 3.6 to 4.3 mEq/L, compared to less than 0.5 mEq/L in the placebo group. By day 30, sodium had risen by roughly 6.2 mEq/L on tolvaptan versus about 1.7 mEq/L on placebo.
For hyponatremia, the typical starting dose is 15 mg once daily, with adjustments up to a maximum of 60 mg per day depending on how your sodium levels respond. Treatment is initiated in a hospital setting so that sodium can be monitored closely during the first days.
Why Sodium Correction Speed Matters
One of the most important safety concerns with tolvaptan is correcting sodium too quickly. If blood sodium rises faster than about 12 mEq/L in 24 hours, it can trigger a serious neurological condition called osmotic demyelination syndrome. This damages the protective coating around nerve fibers in the brain and can cause difficulty speaking, swallowing problems, muscle stiffness, seizures, or worse.
This is why tolvaptan treatment for hyponatremia starts in a hospital. Your sodium levels are checked frequently during the first 24 to 48 hours so that the dose can be adjusted or fluid given back if sodium is rising too fast. The drug itself isn’t inherently dangerous at normal doses, but its effectiveness at removing water means the correction can overshoot if not carefully managed.
How It Slows Polycystic Kidney Disease
In ADPKD, fluid-filled cysts grow progressively in the kidneys, gradually destroying normal tissue and leading to kidney failure. Vasopressin plays a direct role in this process. When vasopressin binds to V2 receptors on kidney cells, it triggers a signaling pathway that promotes cyst growth and fluid secretion into those cysts.
By blocking V2 receptors, tolvaptan interrupts this signaling. The cysts still exist, but they grow more slowly. In clinical studies, tolvaptan treatment reduced the rate of total kidney volume growth. For example, a three-year treatment course was estimated to reduce height-adjusted kidney volume by about 9.6% compared to untreated progression. This slower growth translates to a longer period before kidneys lose enough function to require dialysis or transplant.
For ADPKD, tolvaptan is taken at higher doses (typically split into a morning and afternoon dose) and used long-term, often for years. The goal isn’t to cure the disease but to buy time by slowing its progression.
Side Effects Tied to Its Mechanism
The most predictable side effects of tolvaptan come directly from how it works. Because the drug causes your kidneys to excrete large volumes of water, thirst and frequent urination are extremely common. Patients on tolvaptan for ADPKD often produce several extra liters of urine per day. Drinking enough water to keep up with this fluid loss is essential, and dehydration is a real risk if you don’t.
Liver toxicity is a separate and more serious concern, particularly with the higher doses used for ADPKD. The FDA requires a risk management program for tolvaptan when prescribed for polycystic kidney disease. Under this program, liver enzymes (ALT, AST) and bilirubin are measured before treatment starts, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months, and every 3 months after that. If liver enzymes rise significantly, the drug is stopped. This liver risk has not been a major issue at the lower doses and shorter durations used for hyponatremia, but monitoring is still standard practice.
Other common side effects include dry mouth, dizziness, and, less frequently, elevated blood sugar. Most of these are manageable, but the combination of high urine output and mandatory liver monitoring means tolvaptan requires more active involvement from patients than many other medications.
Why It’s Not a Standard Diuretic
Despite its powerful water-clearing effect, tolvaptan isn’t used as a general-purpose diuretic for conditions like high blood pressure or mild fluid retention. Its cost is significantly higher than conventional diuretics, and its unique risks (rapid sodium shifts, liver toxicity) limit it to situations where its specific mechanism offers a clear advantage. Those situations are primarily severe hyponatremia that hasn’t responded to fluid restriction and ADPKD in patients at high risk of rapid progression. In both cases, the drug’s ability to block vasopressin at the kidney level addresses the underlying problem in a way that standard diuretics cannot.